MURATORE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.213
AS - Asia 4.396
EU - Europa 3.387
SA - Sud America 737
AF - Africa 57
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.823
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.100
SG - Singapore 1.474
CN - Cina 1.450
GB - Regno Unito 925
IT - Italia 716
HK - Hong Kong 635
BR - Brasile 596
SE - Svezia 382
DE - Germania 357
VN - Vietnam 289
RU - Federazione Russa 240
FI - Finlandia 148
UA - Ucraina 138
KR - Corea 126
TR - Turchia 123
FR - Francia 108
BG - Bulgaria 83
ID - Indonesia 72
AR - Argentina 63
NL - Olanda 58
AT - Austria 55
JP - Giappone 49
CA - Canada 40
MX - Messico 36
BD - Bangladesh 33
IN - India 32
IE - Irlanda 28
AU - Australia 25
ES - Italia 25
LT - Lituania 22
IQ - Iraq 21
BZ - Belize 20
EC - Ecuador 20
PL - Polonia 20
ZA - Sudafrica 20
BE - Belgio 17
AE - Emirati Arabi Uniti 16
CL - Cile 13
CO - Colombia 13
HU - Ungheria 12
MA - Marocco 12
PT - Portogallo 12
UZ - Uzbekistan 12
VE - Venezuela 11
PE - Perù 9
CH - Svizzera 8
CZ - Repubblica Ceca 8
KE - Kenya 8
SA - Arabia Saudita 7
KG - Kirghizistan 6
NP - Nepal 6
PK - Pakistan 6
AZ - Azerbaigian 5
EG - Egitto 5
EU - Europa 5
GT - Guatemala 5
PY - Paraguay 5
GR - Grecia 4
IL - Israele 4
IR - Iran 4
PH - Filippine 4
UY - Uruguay 4
AL - Albania 3
DZ - Algeria 3
EE - Estonia 3
MY - Malesia 3
NZ - Nuova Zelanda 3
RO - Romania 3
TH - Thailandia 3
TN - Tunisia 3
TW - Taiwan 3
BO - Bolivia 2
CU - Cuba 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BJ - Benin 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
GY - Guiana 1
IM - Isola di Man 1
JO - Giordania 1
KH - Cambogia 1
KY - Cayman, isole 1
LI - Liechtenstein 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
MW - Malawi 1
NO - Norvegia 1
Totale 17.815
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.459
Fairfield 1.026
Singapore 932
Ashburn 803
Hong Kong 634
Hefei 586
Woodbridge 574
Houston 469
Southend 461
Seattle 440
Chandler 438
Wilmington 323
Cambridge 305
London 290
Ann Arbor 255
Nyköping 235
Beijing 216
Jacksonville 206
Dearborn 193
Modena 175
New York 166
Munich 144
Los Angeles 124
Seoul 122
The Dalles 114
Ho Chi Minh City 108
San Diego 101
Dallas 98
Moscow 98
Helsinki 97
Chicago 89
Princeton 78
Sofia 78
Council Bluffs 73
Buffalo 64
São Paulo 64
Milan 63
Hanoi 61
Shanghai 60
San Jose 57
Jakarta 52
Eugene 51
Nuremberg 37
Redondo Beach 37
Izmir 36
Bologna 34
Kent 34
Columbus 33
Lauterbourg 30
Tokyo 30
Redwood City 29
Rio de Janeiro 29
Salt Lake City 28
Dublin 27
Boardman 26
Elk Grove Village 21
Florence 21
Guangzhou 21
Belize City 20
Amsterdam 19
Brooklyn 19
Vienna 19
Orem 18
Rome 18
Brasília 17
Brussels 17
Haiphong 17
Reggio Emilia 17
Atlanta 16
Frankfurt am Main 16
Kilburn 15
Lappeenranta 15
Mexico City 15
Portsmouth 15
Warsaw 15
Denver 13
Falls Church 13
Johannesburg 13
Ankara 12
Montreal 12
Norwalk 12
Phoenix 12
Tampa 12
Toronto 12
Chennai 11
Las Vegas 11
Parma 11
Reggio Nell'emilia 11
Tashkent 11
Bremen 10
Nanjing 10
Palermo 10
Porto Alegre 10
Sterling 10
Düsseldorf 9
Jefferson City 9
Melbourne 9
Stockholm 9
Thái Bình 9
Belo Horizonte 8
Totale 13.012
Salva come PNG Salva come JPEG
Nome #
Visual loss and other cranial ischaemic complications in giant cell arteritis 278
Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature 266
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 265
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility 255
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 254
Biotherapies in large vessel vasculitis 250
Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease 246
Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT 245
Recent advances in the diagnosis and treatment of polymyalgia rheumatica 243
Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis 240
Comparison between colour duplex sonography findings and different histological patterns of temporal artery 239
Biologics in vasculitides: Where do we stand, where do we go from now? 237
Comment on: Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature: Reply 235
Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica 232
Increased expression of interleukin-22 in patients with giant cell arteritis 229
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease 223
Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study 221
Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study 220
Imaging of vasculitis: State of the art 220
Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations 218
MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis 217
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study 214
No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis 206
L-arginine supplementation normalizes bone turnover and preserves bone mass in streptozotocin-induced diabetic rats 205
Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study 203
Large-Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease? 203
Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis 202
Incidence, prevalence and survival of biopsy-proven giant cell arteritis in Northern Italy during a 26-year period 201
Unmet Needs in the Pathogenesis and Treatment of Vasculitides 200
Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab 200
Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia 200
Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? 198
Statin use in giant cell arteritis: a retrospective study 195
Tocilizumab for the treatment of giant cell arteritis 191
Mycophenolate mofetil in primary central nervous system vasculitis 190
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? 189
Large-vessel giant cell arteritis: a cohort study 186
Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma 182
Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis 181
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches 180
Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature 177
Updates on the diagnosis and monitoring of giant cell arteritis 176
L30. Assessment of vasculitis extent and severity 170
Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study 168
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis 168
Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study 165
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study 164
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 162
The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis 160
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 155
Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients 152
Extra-articular rheumatoid arthritis imaged by [18F]FDG-PET/CT 151
Survival predictors in biopsy-proven giant cell arteritis: A northern Italian population-based study 149
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 143
Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica 143
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 140
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 139
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients 137
Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy 135
Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis 134
Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis 133
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 131
Isolated vasculitis of the lower extremities in a patient with polymyalgia rheumatica and giant cell arteritis 131
Distribution patterns of 18F-fluorodeoxyglucose in large vessels of Takayasu's and giant cell arteritis using positron emission tomography 131
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study 130
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 130
Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy 125
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 124
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 124
Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study 120
Giant Cell Arteritis and Polymyalgia Rheumatica 119
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 118
IgG4-associated sclerosing mesenteritis 116
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 115
Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years 114
Corrigendum to: Increased expression of interleukin-22 in patients with giant cell arteritis 114
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 113
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study 112
Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study 111
Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells 111
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 110
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 110
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis 110
Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap? 109
Development of the Takayasu Arteritis Integrated Disease Activity Index 105
Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases 105
FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS 104
Role of miR-146a and miR-146b in Giant Cell Arteritis. 104
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 103
What to Know About Biopsy Sampling and Pathology in Vasculitis? 102
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 100
Insight into giant cell arteritis pathogenesis by NanoString nCounter gene expression profiling in temporal artery biopsies 100
miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis 99
Eosinophilic giant cell arteritis: A different subset of disease? 99
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies 98
The Role of PET in the Diagnosis and Disease Activity Assessment in Large Vessel Vasculitis 97
Trattamento con Tocilizumab in monoterapia dopo trattamento con glucocorticoidi per breve periodo in pazienti con arterite a cellule giganti con coinvolgimento dei grandi vasi: effetti sui checkpoint immunitari solubili 96
Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis 96
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study 95
Response to: COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: A cross-sectional patient survey study' by Cuceoglu et al 94
Totale 16.305
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.008 0 0 0 0 0 138 114 225 103 168 142 118
2021/20221.390 77 95 104 83 45 116 131 52 150 114 262 161
2022/20231.409 166 151 111 113 147 183 44 108 206 25 76 79
2023/20241.082 19 70 50 100 190 134 98 172 28 27 63 131
2024/20255.015 138 48 78 342 1.060 826 408 223 534 326 508 524
2025/20264.056 652 414 774 873 960 383 0 0 0 0 0 0
Totale 18.039